Inhalational anaesthetics
The physical properties of the volatile agents and nitrous oxide, uptake and distribution and the factors that change the speed of induction and emergence, minimum alveolar concentration and what alters it, mechanisms of action, effects on each organ system, toxicity, and a comparison of nitrous oxide, sevoflurane, desflurane and isoflurane.
By the end of this page you should be able to
- Describe the physical properties that matter for an inhalational agent, including saturated vapour pressure, boiling point and partition coefficients.
- Explain the uptake and distribution of an inhalational agent and the factors that speed or slow the rise in alveolar concentration, including the concentration and second gas effects.
- Define minimum alveolar concentration and list the factors that increase and decrease it.
- Describe the effects of the volatile agents on the cardiovascular, respiratory and central nervous systems, and their toxicity.
- Compare nitrous oxide, sevoflurane, desflurane and isoflurane, and describe the specific pharmacology of nitrous oxide.
Physical properties
The modern volatile agents are halogenated ethers: isoflurane, sevoflurane and desflurane. Halogenation makes them non-flammable; fluorination lowers solubility and metabolism. They are liquids at room temperature and are delivered as vapours from vaporisers. Nitrous oxide is a gas stored as a liquid under pressure.
The properties that matter are: saturated vapour pressure and boiling point (which decide how the agent is vaporised; desflurane boils at about 23 °C, so it needs a heated, pressurised vaporiser); the blood-gas partition coefficient (the ratio of concentrations in blood and gas at equilibrium, a measure of blood solubility, which governs speed of onset and offset); the oil-gas partition coefficient (a measure of lipid solubility, which correlates with potency, the Meyer-Overton relationship); stability with soda lime and light; pungency; and the fraction metabolised.
Approximate blood-gas coefficients: desflurane 0.45, nitrous oxide 0.47, sevoflurane 0.65, isoflurane 1.4. Lower means less dissolves in blood, so alveolar and brain partial pressures rise faster. Potency runs the other way to oil-gas solubility: isoflurane is the most potent of the three ethers, desflurane the least, and nitrous oxide is so weak that it cannot produce anaesthesia on its own at atmospheric pressure.
Uptake and distribution
The effect depends on the partial pressure in the brain, which follows the alveolar partial pressure closely because the brain is well perfused. So the key question is how fast the alveolar fraction (FA) approaches the inspired fraction (FI): the FA/FI curve.
Delivery to the alveoli is opposed by uptake into blood. Uptake = blood-gas coefficient × cardiac output × (alveolar minus mixed venous partial pressure) ÷ barometric pressure. Anything that reduces uptake makes FA rise faster.
Faster rise (faster induction): low blood solubility; high inspired concentration (overpressure); high alveolar ventilation; low cardiac output (less agent carried away, which is why shocked patients and the elderly can be induced quickly and deeply); and a falling mixed venous to alveolar gradient as tissues fill. Functional residual capacity dilutes the inspired gas at first; a small FRC (children, pregnancy) speeds the rise.
Slower rise: high solubility, high cardiac output (anxiety, hyperthyroidism), low ventilation, and V/Q mismatch. A right to left shunt slows induction most for poorly soluble agents, because the shunted blood dilutes arterial partial pressure and there is little extra uptake to compensate.
Tissues fill in order of perfusion: the vessel-rich group (brain, heart, kidney, liver; about three quarters of cardiac output but less than a tenth of body mass) within minutes, then muscle, then fat over hours, which holds a great deal of the more lipid-soluble agents.
The concentration effect: the higher the inspired concentration, the faster FA/FI rises, because uptake of a large volume of gas concentrates what remains and draws in more gas to replace it. It matters only for nitrous oxide, which is used at high concentration. The second gas effect: the rapid uptake of nitrous oxide also concentrates a volatile agent given with it, speeding its rise.
Elimination is the mirror image, mainly through the lungs. Recovery is faster with low solubility and high ventilation, and slows after long anaesthetics as muscle and fat fill. Diffusion hypoxia occurs when nitrous oxide is stopped: it floods out of blood into the alveoli and dilutes oxygen and carbon dioxide, so supplemental oxygen is given for a few minutes.
Minimum alveolar concentration
MAC is the alveolar concentration, at steady state and one atmosphere, that prevents movement in response to a standard surgical stimulus in 50% of subjects. It is a measure of potency (an ED50) for immobility, which is mediated mostly at the spinal cord; awareness and amnesia are suppressed at lower concentrations (MAC-awake is roughly a third to a half of MAC). MAC values are roughly additive, so half a MAC of two agents is about one MAC.
MAC is reduced by: increasing age (about 6% per decade after the first year), hypothermia, pregnancy, opioids, benzodiazepines, alpha-2 agonists, other anaesthetics, acute alcohol intoxication, hyponatraemia, severe hypotension and hypoxaemia. MAC is increased by: infancy (peaking at around six months), hyperthermia, chronic alcohol use, hypernatraemia, sympathomimetics and drugs that raise central catecholamines, and red hair (melanocortin-1 receptor variants). Unchanged by: sex, duration of anaesthesia, thyroid function, and potassium and acid-base changes within the usual range.
Mechanism and organ effects
- Mechanism: no single site. Volatile agents enhance GABA-A and glycine receptor function and open two-pore domain potassium channels (hyperpolarising neurones), and reduce excitatory transmission at nicotinic and glutamate receptors. Nitrous oxide and xenon are NMDA antagonists. Immobility is largely a spinal effect; unconsciousness and amnesia are cortical and thalamic.
- Cardiovascular: dose-dependent fall in blood pressure, mainly from reduced systemic vascular resistance (isoflurane, desflurane, sevoflurane) with some myocardial depression; heart rate is preserved or rises (isoflurane and desflurane more than sevoflurane). Desflurane at high or rapidly increasing concentrations causes sympathetic stimulation with tachycardia and hypertension. They sensitise the myocardium to catecholamines less than the old alkane halothane did. They blunt the baroreflex. Volatile agents have preconditioning effects on ischaemic myocardium in experimental models.
- Respiratory: dose-dependent fall in tidal volume with a rise in rate, so minute ventilation falls, dead space fraction rises and carbon dioxide rises; the ventilatory response to carbon dioxide and to hypoxia is depressed even at subanaesthetic concentrations. They are bronchodilators (sevoflurane is well tolerated for inhalational induction because it is non-pungent; desflurane and isoflurane are pungent and irritate the airway, causing coughing and laryngospasm). They inhibit hypoxic pulmonary vasoconstriction and mucociliary function.
- Central nervous system: reduce cerebral metabolic rate but are direct cerebral vasodilators, so at higher concentrations flow and intracranial pressure rise and flow-metabolism coupling is lost; carbon dioxide reactivity is preserved. Sevoflurane can cause epileptiform EEG activity at high concentrations and emergence agitation in children.
- Other: uterine relaxation (dose-dependent, relevant to postpartum haemorrhage), potentiation of non-depolarising neuromuscular blockers, and triggering of malignant hyperthermia in susceptible patients.
Toxicity and the individual agents
- Metabolism: sevoflurane about 2 to 5%, isoflurane about 0.2%, desflurane less than 0.1%. Sevoflurane releases inorganic fluoride (without clinically important renal injury in practice). With strong-base absorbents, sevoflurane forms compound A, nephrotoxic in rats, which increases at low fresh gas flows and high absorbent temperature. Dry absorbent with desflurane (and less so isoflurane) can form carbon monoxide.
- Hepatitis: the old alkane halothane caused immune-mediated hepatitis via a trifluoroacetylated metabolite; isoflurane and desflurane form much less of this, and sevoflurane is metabolised differently.
- Nitrous oxide: a weak anaesthetic but a useful analgesic (NMDA antagonism and opioidergic effects). Because it is 34 times more soluble in blood than nitrogen, it enters air-filled spaces faster than nitrogen can leave, so it expands compliant spaces (pneumothorax, bowel, air embolus) and raises pressure in non-compliant ones (middle ear, tube cuffs, the eye after intraocular gas). It oxidises the cobalt in vitamin B12, inactivating methionine synthase, which with prolonged or repeated exposure causes megaloblastic change, subacute combined degeneration and raised homocysteine. It increases postoperative nausea, causes diffusion hypoxia on stopping, and is a potent greenhouse gas and ozone-depleting agent.
- Environment: desflurane has by far the largest global warming impact of the volatile agents, followed by isoflurane and sevoflurane; nitrous oxide is long-lived in the atmosphere. Low fresh gas flows and scavenging reduce waste.
- Xenon: an inert NMDA antagonist with very low blood solubility, little cardiovascular depression, but high cost and limited supply.
What gets marks
- Draw the FA/FI curve with agents in order of blood solubility, then list the factors that move it.
- Separate solubility in blood (speed) from solubility in oil (potency).
- Define MAC exactly (alveolar, steady state, one atmosphere, 50%, surgical stimulus), then give factors that raise, lower and do not change it.
- Compare agents in a fixed order: physical properties, uptake, potency, organ effects, metabolism and toxicity, environment.
Common traps
- Saying high cardiac output speeds induction; it slows the rise in alveolar concentration.
- Confusing the concentration effect (one gas, its own concentration) with the second gas effect (a companion gas).
- Saying MAC measures depth of hypnosis; it is about movement, mostly spinal.
- Saying volatile agents reduce cerebral blood flow; they lower metabolism but dilate cerebral vessels.
- Forgetting that nitrous oxide expands spaces because it is more soluble than nitrogen, not because it is less.
Where this meets anaesthesia
- Induction with a volatile agent is faster when cardiac output is low, so shocked patients reach deep anaesthesia quickly.
- Nitrous oxide expands air-filled spaces, so it is avoided with pneumothorax, bowel obstruction, middle ear surgery and intraocular gas.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
What determines the speed of induction with an inhalational agent?
Show answer
- Brain partial pressure follows alveolar partial pressure; the question is how fast FA approaches FI.
- Delivery: inspired concentration, alveolar ventilation, FRC.
- Uptake: blood-gas solubility, cardiac output, alveolar to mixed venous gradient.
- Low solubility, high inspired concentration, high ventilation and low cardiac output speed it; shunt slows it, more so for insoluble agents.
- Concentration and second gas effects with nitrous oxide.
- 2.
Define MAC and tell me what changes it.
Show answer
- Alveolar concentration at steady state and one atmosphere preventing movement to a surgical incision in 50% of subjects.
- Mostly a spinal effect; MAC-awake is lower; values are roughly additive.
- Decreased: age, hypothermia, pregnancy, opioids, sedatives, alpha-2 agonists, acute alcohol, hyponatraemia, severe hypotension or hypoxaemia.
- Increased: infancy, hyperthermia, chronic alcohol, hypernatraemia, sympathomimetics, red hair.
- Unchanged: sex, duration, thyroid status, mild acid-base and potassium changes.
- 3.
Explain the concentration and second gas effects.
Show answer
- Concentration effect: when a gas is given at high inspired concentration, its large volume uptake concentrates the remaining alveolar gas and draws in more gas, speeding its own rise.
- Only clinically important for nitrous oxide at high concentration.
- Second gas effect: the same uptake of nitrous oxide concentrates a volatile agent and oxygen given with it.
- The reverse at the end of anaesthesia causes diffusion hypoxia.
- 4.
Compare sevoflurane and desflurane.
Show answer
- Desflurane is less soluble in blood, so faster onset and offset, but less potent and pungent; boils near room temperature, needing a heated pressurised vaporiser.
- Sevoflurane is non-pungent, so suited to inhalational induction; more metabolised with fluoride release and compound A with strong-base absorbents.
- Desflurane causes sympathetic stimulation with rapid increases; can form carbon monoxide with dry absorbent.
- Desflurane has a much larger global warming impact.
- 5.
What are the effects of volatile agents on the cardiovascular system?
Show answer
- Dose-dependent hypotension, mainly from reduced systemic vascular resistance, plus myocardial depression.
- Heart rate maintained or increased; blunted baroreflex.
- Desflurane can cause sympathetic surge with rapid changes in concentration.
- Less catecholamine sensitisation than halothane; possible preconditioning effects.
- 6.
How do volatile agents affect breathing?
Show answer
- Tidal volume falls, rate rises, minute ventilation falls, dead space fraction and carbon dioxide rise.
- Depressed ventilatory responses to carbon dioxide and especially to hypoxia, even at low concentrations.
- Bronchodilation; airway irritation with pungent agents.
- Inhibit hypoxic pulmonary vasoconstriction, worsening V/Q matching; reduce mucociliary clearance.
- 7.
Tell me about the pharmacology of nitrous oxide.
Show answer
- Gas stored as a liquid; low blood solubility; weak anaesthetic, good analgesic; NMDA antagonist.
- Expands air-filled spaces because it is far more soluble than nitrogen; raises pressure in closed spaces.
- Inactivates methionine synthase by oxidising vitamin B12: megaloblastic change, neuropathy, raised homocysteine with prolonged exposure.
- Diffusion hypoxia, nausea, and environmental harm.
- 8.
What happens to cerebral blood flow and intracranial pressure with volatile agents?
Show answer
- Cerebral metabolic rate falls, which tends to lower flow.
- Direct vasodilatation increases flow, increasingly at higher concentrations, so coupling is lost.
- Intracranial pressure can rise in patients with low intracranial compliance.
- Carbon dioxide reactivity is preserved, so ventilation can partly offset it.
- 9.
Why does recovery take longer after a long anaesthetic?
Show answer
- Tissues beyond the vessel-rich group, particularly muscle and fat, have taken up agent.
- On stopping, they return agent to the blood, slowing the fall in alveolar and brain partial pressure.
- Greater effect with more lipid-soluble and blood-soluble agents.
- Context-sensitive decrement times describe this; low solubility agents are least affected.
Practise this week
- Physiology Bench: move the graphs yourself
- Primary MCQs: pharmacology
- Primary SAQs, marked part by part
- Primary vivas
- Viva Examiner: practise answering aloud
Week 4 in the other subjects
- Physiology: Lung mechanics and the work of breathing
- Measurement and equipment: Gas laws, flow and oxygen delivery
Not affiliated with the Australian and New Zealand College of Anaesthetists (ANZCA). Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.